Research Site

Wuppertal 42287

3 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, Atopic Dermatitis, Breast Cancer, Breast Cancer, Early Breast Cancer, Carcinoma, Non-Small Cell Lung, Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis, Cutaneous Lupus Erythematosus, Dyslipidemia, Gastroesophageal Reflux Disease (GERD), Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

Studies at this site

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus — Running, not enrolling
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) — Running, not enrolling
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) — Completed
• Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis — Completed
• Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects — Completed
• Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) — Completed
• Phase 3/Safety & Efficacy of Esomeprazole in Infants — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early
• A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome — Completed